-
公开(公告)号：US20200069740A1
公开(公告)日：2020-03-05
申请号：US16491974
申请日：2018-03-08
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Hikari Hasegawa , Masayo Yumoto , Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC: A61K35/28
Abstract: The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and/or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.
-
Patent Agency Ranking
公开(公告)号：US20190117701A1
公开(公告)日：2019-04-25
申请号：US16096973
申请日：2017-04-27
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Eiko Uno , Masayo Yumoto , Mihoko Yoshino , Xuan Trung Ngo , Hiroyuki Nishida , Akiko Uetani
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
-
公开(公告)号：US20180161262A1
公开(公告)日：2018-06-14
申请号：US15577552
申请日：2016-05-26
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Tomohiro Tsuda , Masayo Yumoto
CPC classification number: A61K8/65 , A61K8/345 , A61K8/64 , A61K38/06 , A61K38/07 , A61K2800/592 , A61K2800/78 , A61Q19/00 , G01N33/502 , G01N33/5029 , G01N33/5073
Abstract: The present invention relates to a cosmetic method comprising applying a migration imparting agent for adipose-derived stem cells to the skin, thereby allowing adipose-derived stem cells to migrate to the dermal layer and improving a skin condition. The present invention also relates to an external skin preparation for use in the cosmetic method, the external skin preparation comprising a migration imparting agent allowing adipose-derived stem cells to migrate to the dermal layer by application to the skin. The present invention further relates to a migration imparting agent for adipose-derived stem cells, comprising at least one of a polyol compound and a hydrophilic biomaterial. The present invention further relates to a method of screening for a component for use in a cosmetic method for improving a skin condition, comprising evaluating migratory activity of adipose-derived stem cells by using a prepared medium containing a sample.
-
公开(公告)号：US11707488B2
公开(公告)日：2023-07-25
申请号：US15755859
申请日：2016-08-29
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Masayo Yumoto , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0662 , C12N2501/998 , C12N2510/00 , Y02A50/30
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
-
公开(公告)号：US11179420B2
公开(公告)日：2021-11-23
申请号：US16096973
申请日：2017-04-27
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Eiko Uno , Masayo Yumoto , Mihoko Yoshino , Xuan Trung Ngo , Hiroyuki Nishida , Akiko Uetani
IPC: C12N5/0775 , A61K35/28 , A61P29/00
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
-
公开(公告)号：US20180333436A1
公开(公告)日：2018-11-22
申请号：US15755859
申请日：2016-08-29
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Masayo Yumoto , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0662 , C12N2501/998 , C12N2510/00 , Y02A50/411
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
